OSM and central nervous system cancer: High expression of oncostatin M (OSM) receptor OSMR has recently emerged as a poor prognosis factor in several malignancies such as acute myeloblastic leukemia (AML), gliomas, pancreatic, gastric and kidney carcinomas.